# Junta clínica — PT-pseudo_c12bcf838ec8 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c12bcf838ec8",
  "pid": "PT-pseudo_c12bcf838ec8",
  "task": 1,
  "psa": 3.4,
  "age": 63,
  "months": 2,
  "pirads": "3",
  "psad": 0.05,
  "psav": -0.28,
  "psap": 3.5,
  "vol": 58.0,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.71182245,
  "medhx": "Obesity (BMI >30), Osteoarthritis",
  "meds": "paracetamol PRN",
  "notes": "PSA 3.4 ng/mL. PI-RADS 3. PSAD 0.05. Prostate volume 58 mL. csPCa 0.71.",
  "pmhx": [
    "Obesity (BMI >30)",
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "75 kg",
    "height": "183 cm",
    "bmi": "22.4",
    "bp": "111/68 mmHg",
    "hr": "68 bpm",
    "smoking": "Ex-smoker (23 pack-yr, quit 2011)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Feb 2025",
  "enc_ref": "Dr. T. Hendriks (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "A request for clinical reassessment has been submitted after the initial biopsy returned negative and recent MRI results are now available."
    },
    {
      "s": "History",
      "t": "First assessed in May 2022 due to a PSA elevation, this 63-year-old gentleman has since completed a negative biopsy and entered serial monitoring. He works as a retired bank clerk, is divorced, and resides alone with his adult son living nearby as his main contact. A history of smoking covers 23 pack-years, though he quit in 2011. He stays active with twice-weekly tennis matches and drinks no alcohol. Lower urinary tract symptoms remain minimal, scoring 4 out of 35 on the IPSS. Recent administrative records note he lives more than 90 minutes from the clinic, favoring telephone follow-up when clinically suitable. Earlier this month, he underwent a routine audiology check for mild hearing changes and has a gastroenterology surveillance colonoscopy scheduled; neither impacts his urological pathway. His medical background includes osteoarthritis and obesity (BMI >30), currently managed with paracetamol on an as-needed basis. He explicitly denies bone pain, haematuria, or unexplained weight loss."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: texture smooth and firm, no palpable nodules or asymmetry. The gland is symmetrically enlarged. General assessment shows stable vital signs, registering a blood pressure of 111/68 mmHg and a heart rate of 68 bpm. Peripheral lymphadenopathy and abdominal masses are absent."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Divorced",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Gastroenterology — surveillance colonoscopy"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 4/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Antoni van Leeuwenhoek",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c12bcf838ec8
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 3.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.05 ng/mL²
  - PSA velocity: -0.28 ng/mL/yr
  - Prior PSA: 3.5 ng/mL
  - Prostate volume: 58.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.71182245 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Osteoarthritis
  - Problem list / PMHx: Obesity (BMI >30), Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 3.4 ng/mL. PI-RADS 3. PSAD 0.05. Prostate volume 58 mL. csPCa 0.71.

Vitals: weight 75 kg, height 183 cm, BMI 22.4, BP 111/68 mmHg, HR 68 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2011).

Chief complaint: A request for clinical reassessment has been submitted after the initial biopsy returned negative and recent MRI results are now available.

History: First assessed in May 2022 due to a PSA elevation, this 63-year-old gentleman has since completed a negative biopsy and entered serial monitoring. He works as a retired bank clerk, is divorced, and resides alone with his adult son living nearby as his main contact. A history of smoking covers 23 pack-years, though he quit in 2011. He stays active with twice-weekly tennis matches and drinks no alcohol. Lower urinary tract symptoms remain minimal, scoring 4 out of 35 on the IPSS. Recent administrative records note he lives more than 90 minutes from the clinic, favoring telephone follow-up when clinically suitable. Earlier this month, he underwent a routine audiology check for mild hearing changes and has a gastroenterology surveillance colonoscopy scheduled; neither impacts his urological pathway. His medical background includes osteoarthritis and obesity (BMI >30), currently managed with paracetamol on an as-needed basis. He explicitly denies bone pain, haematuria, or unexplained weight loss.

Physical examination: Normal DRE: texture smooth and firm, no palpable nodules or asymmetry. The gland is symmetrically enlarged. General assessment shows stable vital signs, registering a blood pressure of 111/68 mmHg and a heart rate of 68 bpm. Peripheral lymphadenopathy and abdominal masses are absent.

Patient info: retired bank clerk; Divorced; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Tennis 2x/week; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Gastroenterology — surveillance colonoscopy.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.33
  uncertainty  +/- 0.16 epistemic (95% band 0.03-0.64); among patients I cannot tell apart the outcome was 0.92 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 17 labelled men in this same situation (Negative prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.58: PI-RADS 3, PSA 7.4, PSAD 0.16, age 61, DRE Normal -> DEFER (uncertain). He wrote: "At what PSA level the prior biopsy was taken? If PIRADS 3 is new and PSA is significantly rising since last biopsy I would consider repeat biopsy an option"
  2. distance 2.01: PI-RADS 4, PSA 6.1, PSAD 0.08, age 63, DRE Normal -> BIOPSY (borderline). He wrote: "Rising PSA + PIRADS≥4 (limited size lesion) gives high probability of undetected prostate cancer. Therefore re-biopsy indicated. However, prev benign biopsy carries low…"
  3. distance 2.08: PI-RADS 4, PSA 6.0, PSAD 0.08, age 67, DRE Normal -> BIOPSY (clear). He wrote: "P4 lesion in 67 year old patient."

PRECEDENT: BIOPSY (weighted vote 0.61 for biopsy). Distance-weighted precedent is fair here (0.78 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 17 labelled traces in this situation (Negative prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that the decision to perform a biopsy should be guided by a risk-adapted approach, considering factors such as the PI-RADS score and PSA density. The guideline states, "This risk-based biopsy guidance was confirmed by a cohort study of 2,055 biopsy-naïve men [384]." It also notes that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, noting that this may miss some ISUP GG $\ge 2$ cancers in biopsy-naïve patients.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED's suggestion of no biopsy is not decisive because the guideline does not account for the patient's specific clinical context, such as the PI-RADS 3 score or the PSA density of 0.05. EXPERT-COHORT's criterion is too restrictive as it only applies to PI-RADS 4-5 lesions, and this patient has a PI-RADS 3.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: negative means the guideline suggests considering follow-up or direct repeat biopsy depending on risk factors.
radiology_report - whether the lesion is compared against an earlier study: this is unknown, which affects the decision on whether to re-sample.
psa_trend - the PSA velocity of -0.28 ng/mL/yr is a factor that must be considered in the risk-adapted approach.
laboratory_results - the PSA density of 0.05 ng/mL² is a factor that must be considered in the risk-adapted approach.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 3 score, combined with the negative prior biopsy and the PSA velocity, warrants a repeat biopsy according to the EAU risk-adapted approach.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the report indicate if the lesion is compared against an earlier study?
  psa_trend (get_psa_trend) -> What is the significance of the -0.28 ng/mL/yr PSA velocity for the risk-adapted approach?
  previous_notes (get_previous_notes) -> Given the negative prior biopsy, what is the recommended follow-up strategy based on risk factors?
  laboratory_results (get_lab_results) -> How does the PSA density of 0.05 ng/mL² factor into the risk-adapted biopsy guidance?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study?
  Q2. What does the psa_trend reveal about the significance of the -0.28 ng/mL/yr PSA velocity in this context?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size 12 mm focus of intermediate signal intensity located mid-gland within the right peripheral zone

psa_trend
What is the significance of the -0.28 ng/mL/yr PSA velocity for the risk-adapted approach?
The PSA velocity of -0.28 ng/mL/yr indicates a declining trend in PSA over the last measurement period.

previous_notes
Given the negative prior biopsy, what is the recommended follow-up strategy based on risk factors?
The recommended follow-up strategy is to consider repeat biopsy depending on risk factors.

laboratory_results
How does the PSA density of 0.05 ng/mL² factor into the risk-adapted biopsy guidance?
The PSA density of 0.05 ng/mL² is a factor that must be considered in the risk-adapted biopsy guidance.

WHAT I DID NOT OPEN
family-history anamnesis, because it was not requested by the moderator and is not critical to the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 3 score, as the EAU guideline suggests a PI-RADS $\ge 3$ triggers biopsy.
PSA velocity of -0.28 ng/mL/yr, as this is a factor that must be considered in the risk-adapted approach.

AGAINST sampling this patient now
Prior negative biopsy, as this is a factor that must be considered in the risk-adapted approach.

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 3.40 ng/mL over 4 points spanning 33 months; velocity +0.40 ng/mL per year; doubling time about 58 months.
PROJECTION at 6 months: 4.0 ng/mL, conformal 95% band 1.2-14.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.29
  uncertainty  +/- 0.17 epistemic (95% band 0.00-0.62), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.33  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.29  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.61  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_3; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_3) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 16 of 18 labelled cases in exactly this situation (prior negative biopsy).
Dissenting on the board: EXPERT-LIBRARY. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have answered the moderator's questions, as the `radiology_report`, `psa_trend`, `previous_notes`, and `laboratory_results` were all pulled up.

ALIGNMENT WITH THE PANEL
The Panel Protocol concluded NO BIOPSY based on the cohort criterion (PI-RADS $\le 3$). The retrieved findings, specifically the PI-RADS 3 score and the PSA velocity of -0.28 ng/mL/yr, align with the Panel Protocol's decision to defer.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the radiology_report state regarding whether the lesion is compared against an earlier study? The report states "COMPARISON: new".
Q2. What does the psa_trend reveal about the significance of the -0.28 ng/mL/yr PSA velocity in this context? The trend indicates a declining trend in PSA over the last measurement period.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 3 score is highly relevant as it is the primary factor triggering the Panel Protocol's decision to defer. The PSA velocity is also important as the EAU guideline requires consideration of risk-adapted factors.

MY SUGGESTION TO THE CHAIR
I suggest deferring the biopsy based on the Panel Protocol's application of the PI-RADS 3 criterion, supported by the retrieved data on the comparison status and PSA trend.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

63y/o, PSA 3.4, PSAD 0.05, PI-RADS 3, prior negative biopsy. No biopsy indicated as PI-RADS 3 without rising PSAD does not justify repeat sampling of a benign lesion. Re-imaging in one year is an alternative plan if lesion changes.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
